DBV Technologies SA Sponsored ADR

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DBV Technologies S.A. (DBVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.

Down -25.23% in 4 Weeks, Here's Why You Should You Buy the Dip in DBV Technologies S.A. (DBVT)

Montrouge, France, November 9, 2023 DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers Viaskin Peanut showed improvement between months 12 and 24 of treatment across all efficacy parameters. Notably, 81.3% of subjects who completed the oral food challenge reached an eliciting dose of ≥1,000 mg after 24 months of treatment.

DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers

Montrouge, France, November 2, 2023 DBV Technologies to Present New Data at ACAAI 2023 New data to include late-breaking abstract detailing interim 12-month results from the ongoing Phase 3 open-label extension to the EPITOPE trial (EPOPEX) of Viaskin™ Peanut in peanut-allergic toddlers. DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that new data on the use of Viaskin™ Peanut (DBV712) 250 μg in peanut-allergic toddlers will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, which is being held Thursday, November 9 – Monday, November 13, 2023, in Anaheim, CA.

DBV Technologies to Present New Data at ACAAI 2023

DBV Technologies S.A. (NASDAQ:DBVT ) Q3 2023 Earnings Conference Call October 31, 2023 5:00 PM ET Company Participants Katie Matthews - Head of Investor Relations Daniel Tassé - Chief Executive Officer Pharis Mohideen - Chief Medical Officer Conference Call Participants Rajan Sharma - Goldman Sachs Operator Welcome to the DBV's Third Quarter Financial Results and Business and Regulatory Update Conference Call.

DBV Technologies S.A. (DBVT) Q3 2023 Earnings Call Transcript

Montrouge, France, October 31, 2023 DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies and Reports Third Quarter 2023 Financial Results DBV has received written feedback from the U.S. Food and Drug Administration (FDA) clarifying design elements for both the COMFORT Toddlers and COMFORT Children supplemental safety studies. Both supplemental safety studies will have harmonized, simplified protocol language on how the product should be used.

DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies and Reports Third Quarter 2023 Financial Results

Montrouge, France, October 27, 2023 DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, October 31st, at 5:00 p.m. ET to review third quarter 2023 financial results and provide a business update.

DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update

Montrouge, France, October 16, 2023 DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Virginie Boucinha as its Chief Financial Officer, effective November 6, 2023. An experienced financial and operations executive, Virginie will report directly to Daniel Tassé, Chief Executive Officer, and serve as a member of the Executive Committee.

DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer

Montrouge, France, September 5, 2023 D BV Technologies to Participate in Upcoming Investor Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the company will participate in the H.C. Wainwright Annual Global Investment Conference taking place on September 11th −13th in New York, NY.

DBV Technologies to Participate in Upcoming Investor Conference

DBV Technologies S.A. (NASDAQ:DBVT ) Q2 2023 Earnings Call July 31, 2023 5:00 PM ET Company Participants Katie Matthews - Head of Investor Relations Daniel Tassé - Chief Executive Officer Sébastien Robitaille - Chief Financial Officer Pharis Mohideen - Chief Medical Officer Conference Call Participants Jon Wolleben - JMP Securities Operator Good afternoon, and welcome to the DBV Technologies Second Quarter Financial Results Conference Call.

DBV Technologies S.A. (DBVT) Q2 2023 Earnings Call Transcript

GlobeNewswire window.initGradientEffect = function () { } document.addEventListener('DOMContentLoaded', function () { const extendedTableZoomElements = document.querySelectorAll('.extended-table-zoom'); if (extendedTableZoomElements && extendedTableZoomElements.length > 0) { window.Stickyfill.add(extendedTableZoomElements); } const socialMediaSideBarContainerElement = document.querySelectorAll('.social-media-side-bar-container'); if (socialMediaSideBarContainerElement && socialMediaSideBarContainerElement.length > 0) { window.Stickyfill.add(socialMediaSideBarContainerElement); } }, false); window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-ERWPGTJ5X8'); Accessibility: Skip TopNav // used in ui component window.pnrApplicationSettings = { Application:"pnr", SelectedLocale: 'en-US', PnrHostUrl: 'https://www.globenewswire.com', IsAuthenticated: false, ContextUser: '', ApplicationUrl: 'https://www.globenewswire.com', PageContext: '', SubscriptionId: 0, SubscriptionName: '', ArticleLogoUrl: '', ArticleHeadline: '', IsMobileVersion: 'False' === "True" ? true : false, HideLanguageSelection : false, NewsSearchHeading: '', ArticleMediaAttachments: [], AuthSessionExpirationMinutes: '0', AppLogoUrl: 'https://www.globenewswire.com/content/logo/color.svg', ReaderForgotPasswordUrl: 'https://pnrlogin.globenewswire.com/en/reset/confirmresetpassword', ReaderRegisterUrl: 'https://pnrlogin.globenewswire.com/en/register', IsQuickSignInEnabled: true, ReaderAccountBaseUrl: '' }; We're sorry, you encountered a page that doesn't exist.

DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results

Montrouge, France, July 25, 2023 DBV Technologies to Report First Half 202 3 Financial Results and Provide a Corporate Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Monday, July 31st, at 5:00 p.m. ET to report first half 2023 financial results and provide a corporate update.

DBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate Update

Montrouge, France, June 8, 2023 DBV Technologies to Participate i n Upcoming EAACI Congress 2023 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 9 – 11, 2023, in Hamburg, Germany. DBV will present three posters and will also host a symposium and exhibit booth in the EAACI exhibit hall.

DBV Technologies to Participate in Upcoming EAACI Congress 2023

The company's peanut allergy treatment patch could have a wide impact. DBV Technologies currently has no marketed products.

Why Shares of DBV Technologies Jumped Thursday

Montrouge, France, May 10, 2023 DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial D ata E valuating Viaskin™ Peanut in Toddlers Th e New England Journal of Medicine (NEJM) published results that demonstrated epicutaneous immunotherapy (EPIT TM ) with Viaskin Peanut was statistically superior to placebo in desensitizing children to peanut by increasing the peanut dose that triggers allergic symptoms . As stated in an accompanying editorial piece, these data are seen as “ very good news ” for toddlers with peanut allergy, as there are currently no approved treatment options for peanut-allergic children under the age of 4 years.

DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in Toddlers

Montrouge, France, May 4, 2023 DBV Tech nolo gies Reports First Quarter 2023 Financial Results DBV closes Q1 2023 with cash and cash equivalents of $192.3 million . DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported financial results for the first quarter of 2023.

DBV Technologies Reports First Quarter 2023 Financial Results

Montrouge, France, April 19, 2023 D BV Technologies Outlin es Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA The FDA confirmed that the Company's Phase 3 EPITOPE study met the pre-specified criteria for success for the primary endpoint and did not request an additional efficacy study . A dditional safety data will be required to augment the safety data collected from EPITOPE in support of a BLA.

DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA

Montrouge, France, April 12, 2023 DBV Technologies Announces Results of its 202 3 Ordinary and Extraordinary General Meeting Shareholders A pprove d A ll P roposed R esolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today held its Ordinary and Extraordinary General Meeting. The General Meeting was chaired by Michel de Rosen, Chairman of DBV Technologies.

DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting

Denison Mines

Playstudios

Vizsla Silver Corp

VAALCO Energy

Largo Resources LTD

Valens Semiconductor Ltd

While penny stocks almost always attract investors' attention at some point, they're also wildly unpredictable and risky. Yes, some people do enjoy lifechanging profitability.

7 Penny Stocks Sitting in the Sweet Spot

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, will hold its Ordinary and Extraordinary General Meeting (the “General Meeting”) on April 12, 2023, at 10:00 a.m. CET at the Company's headquarters located at 177-181 Avenue Pierre Brossolette – 92120 Montrouge, France.

Ordinary and Extraordinary General Meeting of April 12, 2023

DBV Technologies Update

DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 – 7 Years Old

DBV Technologies S.A. (NASDAQ:DBVT ) Q4 2022 Results Conference Call March 2, 2023 5:00 PM ET Company Participants Anne Pollak - Head IR Daniel Tassé - CEO Sébastien Robitaille - CFO Pharis Mohideen - Chief Medical Officer Conference Call Participants Jon Wolleben - JMP Operator Good day, and welcome to the DBV Technologies Full Year 2022 Financial Results Conference Call.

DBV Technologies S.A. (DBVT) Q4 2022 Earnings Call Transcript

DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document

DBV Technologies Reports Full Year 2022 Financial Results and Business Update

DBV Technologies to Report Full Year 2022 Financial Results and Business Updates on March 2, 2023

News for DBV Technologies SA Sponsored ADR Stock (DBVT)